Patient preferences of treatment administration setting (homecare or hospital)
Time frame · Baseline
Survey responses of patient experience of injections at home and compared to responses of patient experience of injections when given in hospital
Status
Completed
Phase
Not applicable
Enrollment
80
Locations
5
Results
Not posted
Publications
0
Study summary
The aim of the study is to generate real-world evidence to describe the patient experience of administration of Somatuline® Autogel® (lanreotide) in homecare and hospital settings, and the associated impact on healthcare utilisation, societal cost, work productivity and health-related quality of life (HRQoL)
Interventions
No intervention details reported.
Timeline
First posted
Dec 2, 2020
Study start
Apr 27, 2021
Primary completion
Jun 5, 2022
Study completion
Jun 5, 2022
Results posted
Not reported
Registry updated
Dec 17, 2024
Outcomes
Patient preferences of treatment administration setting (homecare or hospital)
Time frame · Baseline
Survey responses of patient experience of injections at home and compared to responses of patient experience of injections when given in hospital
Demographic characteristics of enrolled patients with GEP-NETs
Time frame · Baseline
Age (years); Gender (male, female); Current employment status: full time, part time, unemployed, retired, student, homemaker, unpaid carer)
Clinical characteristics of enrolled patients with GEP-NETs
Time frame · Baseline
Disease duration; Duration of homecare administration of lanreotide; Duration of hospital administration of lanreotide
Patient-reported impact on healthcare resource use
Time frame · Baseline
Assessed using bespoke questionnaire a patient-reported opinion on how homecare administration compares to hospital administration (i.e. much worse / somewhat worse / about the same / somewhat better / much better) for the number of administration setting related aspects described in the protocol, as well as choosing the most applicable answer(s) where applicable.
Patient-reported impact on wider societal costs
Time frame · Baseline
Assessed using bespoke questionnaire a patient-reported opinion on how homecare administration compares to hospital administration (i.e. much worse / somewhat worse / about the same / somewhat better / much better) for the number of administration setting related aspects described in the protocol, as well as choosing the most applicable answer(s) where applicable.
Patient-reported work productivity
Time frame · Baseline
Assessed using the Work Productivity and Activity Impairment Questionnaire: General Health (WPAI:GH) and bespoke questionaire
Description of patient-reported HRQoL
Time frame · Baseline
Assessed using bespoke questionnaire a patient-reported opinion on how homecare administration compares to hospital administration (i.e. much worse / somewhat worse / about the same / somewhat better / much better) for the number of administration setting related aspects described in the protocol, as well as choosing the most applicable answer(s) where applicable.)
Description of patient experience of taking lanreotide in the hospital and homecare settings and reported benefits/limitations of each setting;
Time frame · 1 month
Assessed using qualitative interviews which will be conducted over the telephone by an experienced qualitative interviewer. During the interview semi-structured interview guide will be used, based on guidance and feedback from a clinical expert (specialist nurse) and patient expert(s). The interviews will be primarily guided by the questions in the discussion guide; however, participants will be free to direct the conversation to topics they feel are relevant to their experience.
Description of the impact of the homecare and hospital settings on HRQoL, work productivity, emotional and physical health
Time frame · 1 month
Assessed using qualitative interviews which will be conducted over the telephone by an experienced qualitative interviewer. During the interview semi-structured interview guide will be used, based on guidance and feedback from a clinical expert (specialist nurse) and patient expert(s). The interviews will be primarily guided by the questions in the discussion guide; however, participants will be free to direct the conversation to topics they feel are relevant to their experience.
Eligibility
Inclusion Criteria: * Patients with a diagnosis of GEP-NETs * Patients on prescribed lanreotide Autogel®; * Patients who have switched from hospital to homecare administration setting at least 2 months ago * Patients judged to be on a stable dose; 120mg for tumour control or \>1 injection at same dose for symptom control Exclusion Criteria: * Patients who decline or lack capacity to consent to participate in the study
Study locations
United Kingdom. Showing up to 24 locations stored in the fast local snapshot.
University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom
Cardiff and Vale University LHB
Cardiff, United Kingdom
University Hospitals Coventry and Warwickshire NHS Trust
Coventry, United Kingdom
Liverpool University Hospitals NHS Foundation Trust
Liverpool, United Kingdom
Royal Free London NHS Foundation Trust
London, United Kingdom
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Camurus AB · Gastro-enteropancreatic Neuroendocrine Tumor
Phase 3
Active, not recruiting
332
2026-07
Crinetics Pharmaceuticals Inc. · Carcinoid Syndrome · Carcinoid
Phase 3
Recruiting
141
2026-06
West China Hospital · Neuroendocrine Tumors
Not applicable
Active, not recruiting
500
2026-04
National Health Research Institutes, Taiwan · Neuroendocrine Tumors,Gastroenteropancreatic
Phase 1 / Phase 2
Recruiting
49
2026-04
Assistance Publique - Hôpitaux de Paris · Autosomal Dominant Polycystic Kidney Disease (ADPKD
Phase 3
Completed
159
2026-04
SWOG Cancer Research Network · Pancreatic Carcinoma · Pancreatic Neoplasm
Phase 3
Recruiting
274
2026-03
RayzeBio, Inc. · GEP-NET · Gastroenteropancreatic Neuroendocrine Tumor
Phase 3
Recruiting
338
2026-03
Crinetics Pharmaceuticals Inc. · Carcinoid Syndrome · Carcinoid
Phase 2
Completed
36
2026-03
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.